Antibiotics (intravenous) | 86 (77), 58.9% |
Nebulised bronchodilators | 99, 67.8% |
LABA | 20, 13.7% |
LAMA | 16, 10.9% |
ICS | 19, 13.0% |
Corticosteroids (intravenous) | 104 (96), 71.2% |
Diuretics (intravenous) | 118 (59), 80.8% |
β-blockers | 52, 35.6% |
Antihypertensive drugs | 77, 52.7% |
Antiplatelet drugs | 57, 39.0% |
Anticoagulants | 42, 28.7% |
Statins | 50, 34.2% |
Mineral receptor antagonists | 43, 29.4% |
Digitalis | 9, 6.0% |
Antidiabetic agents (insulin/oral hypoglycaemic drugs) | 29 (17/15), 19.8% |
Proton pump inhibitors | 105, 71.9% |
Antidepressants | 71, 48.6% |
Variable | OR (95% CI) | p-value |
Age | 1.10 (1.03–1.17) | 0.0032 |
Female sex versus male | 0.94 (0.30–2.92) | 0.9108 |
Charlson comorbidity index | 1.86 (1.29–2.69) | 0.0009 |
Anthonisen criteria present versus absent | 0.79 (0.45–1.39) | 0.4067 |
Radiologic signs of overload present versus absent | 0.57 (0.16–2.07) | 0.3944 |
Clinical signs of overload present versus absent | 5.19 (1.05–25.62) | 0.0434 |